The Team

dr Stanislaw-Pikul

Stanisław Pikul, PhD

President of the Management Board

Graduate of PhD studies at the Institute of Organic Chemistry of the Polish Academy of Sciences with postdoctoral fellowships in the teams of prof. M. Isobe at University of Nagoya (Japan) and prof. E. J. Corey at Harvard University (USA). Stanisław was working, among other companies, in Procter & Gamble Pharmaceuticals, Avalon Pharmaceuticals, PTC Therapeutics, and ScinoPharm Pharmaceuticals.
From February 2012 to December 2018 he cooperated with OncoArnedi Therapeutics SA as a co-founder and member of the board. As a Head of Development, he was responsible for the design and execution of preclinical and clinical strategies for drug candidates developed by the Company, the conduct of scientific projects covering CMC, preclinical development, obtaining approvals for clinical trials, and also for the designing and supervision of the clinical trials.
Expert with many years of experience in the management of R&D projects, from the phase of design and drug candidate structure optimisation to the establishment of the preclinical and clinical development strategies, and building and management of science teams.

dr Anna Krause

Anna Krause, PhD

Head of Research and Development, Member of the Board

Pharmaceutical scientist with over 15 years of industrial experience. Expert with great experience in the management of research and development projects of innovative and generic drugs. Anna worked in GlaxoSmithKline for several years and after the closure of the Poznań site, she co-founded PozLab sp. z o.o. where she was the President for 8 years. For over 5 years she was managing the Quality and Control Department and held the function of Qualified Person.
From September 2018 to February 2020 Anna worked at OncoArendi Therapeutics S.A. as Head of Drug Development where she was responsible for CMC area and preclinical development of drug candidates.
She is a co-author of many research and development projects conducted based on the fundings provided by NCBR, NCN, European Commission, and FNP organisations.
Lecturer in “Industrial Pharmacy” postgraduate studies carried out by the Pharmaceutical Department of Medical University of Gdańsk.

dr Joanna Lipner

Joanna Lipner, PhD

Managing Director, Member of the Board

Graduate of the PhD studies at the Institute of Organic Chemistry of the Polish Academy of Sciences. Joanna worked for three years in the Medical Chemistry Department of Celon Pharma SA where she was responsible for the design and synthesis of drug candidates. From 2015 to 2018 Joanna worked at OncoArendi Therapeutics SA, where she was responsible for the management of complex preclinical and clinical innovative drug development projects with budgets of approximately 15 million PLN.
Joanna is a certified Project Manager by IPMA PL and is a graduate of the Drug Registration Academy organised by the Polish Pharmaceutical Society. Asia Grzesik

Joanna Grzesik, MD

Medical Director

An anaesthesiologist with 15 years of experience. Joanna specialises in pathophysiology, pathomechanisms, diagnostics and treatment of pain, with particular emphasis on the pain of premature babies and newborns. Her main scientific interests are studies on the role of pain in shaping the pathological development paths of newborns, with limited possibilities of its treatment due to the lack of data on the safety of many substances, as well as still unexplored phenomena that occur in the organisms of extremely premature babies. Joanna also specialises in the alleviation of the labour pain based on various anesthetic techniques.

Agnieszka Kunicka

Agnieszka Kunicka-Trybus, MSc

Director of Legal Department, Legal Counsuel

Graduate of the Adam Mickiewicz University in Poznań, she has many years of experience in providing legal services to commercial companies and investment funds. She has been working with the pharmaceutical industry since the very beginning of her career. She takes both corporate cases and represents Clients in court proceedings. Her legal knowledge combined with the know-how needed to obtain EU funds make her a perfect contributor to projects co-financed from EU funds. She supervises legal issues related to the company’s activity and development at Pikralida sp. z o.o. as well as those associated with EU grants.

A. Stępieńopt

Anna Stępień

Financial Director

Graduate of the Warsaw School of Economics, finance and banking, and postgraduate Executive MBA at the Warsaw University and University of Illinois at Urbana-Champaign. She has obtained multiple professional qualifications in finance: chartered accountant (ACCA), Polish statutory auditor, Certified Internal Auditor, and management accountant (CIMA). She started her 25+ year professional career in Big 4 audit and business advisory, then gained experience in Finance Director roles in companies of service and production sectors, followed by managerial roles in regional and global structures of finance and operations departments of large international corporations, including TMF, JLL, CBRE. Apart from finance areas, she also managed administration, HR, legal, and IT departments. Anna joined Pikralida in 2022 and is responsible for the company’s finances.

mgr Hanna-Kierońska

Hanna Kierońska, MSc

Head of Drug Technology Department

A specialist in the field of drug formulation technology in the pharmaceutical industry with 18 years of professional experience in the formulation, development, and manufacturing of generic and innovative drugs on laboratory, pilot, and industrial scale, according to GLP and GMP standards. Hanna started her professional career in R&D department of GlaxoSmithKline. As a member of international project teams, she participated in the development of innovative drugs, starting from the preformulation studies, manufacturing of experimental batches in a laboratory and pilot scale, ending with the manufacturing of batches for clinical trials. From 2012 to 2019 Hanna worked at PozLab as a Technological Specialist. She was an author of formulations and the development of generic and innovative drug technologies.

dr Marta Magdycz

Marta Magdycz, PhD

Head of Process Chemistry Department

A specialist in the field of organic and process chemistry with 10 years of professional experience in the development of new synthesis pathways for organic compounds, multistage chemical syntheses, optimisation and scale-up of the active substance manufacturing processes, and transfer of the synthesis processes between the laboratories. Marta started her career as a medicinal chemist at Celon Pharma S.A. R&D department. In 2015-2019 she was working at OncoArendi Therapeutics SA where she was involved in the development of the active substance manufacturing for the preclinical and clinical studies and in the development of new analytical methods for process control. Graduate of the PhD studies at the Institute of Organic Chemistry of the Polish Academy of Sciences.

mgr Anna-Palubicka

Anna Pałubicka, MSc

Head of Pharmaceutical Analysis Department

A specialist in the field of pharmaceutical analysis with 30 years of experience in the development and validation of various analytical methods used for quality control of medicinal products, with a particular emphasis on the chromatographic techniques, as well as in the preparation of the quality documentation for medicinal products, analytical methods transfer documentation, and preparation of the registration documentation for medicinal products. Anna gained her experience in, among others, Poznań Pharmaceutical Works “Polfa”, GlaxoSmithKline, and PozLab.


Magdalena Tyszkiewicz, PhD

Head of Project Management Office

Graduate of the Chemical Department of Technical University of Warsaw. In 2011, she received her PhD with distinction from the Institute of Organic Chemistry at the Polish Academy of Sciences. After a two-year postdoctoral fellowship at the Technical University of Berlin (under a scholarship from the Alexander Humboldt Foundation and BASF) she joined OncoArendi Therapeutics SA (currently Molecure SA) CMC team in 2015. She dealt with the development of synthetic processes and analytical methods for API quality control. Dr. Tyszkiewicz, as a CMC Group Leader and later as a Head of CMC, coordinated the work of the CMC team and was responsible for cooperation with external API and DP manufacturers (CRO), preparation of regulatory documentation (IMPD, IND) and management of the availability and distribution of active substances and medicinal products for the purposes of clinical trials. In May 2023, she joined the Pikralida team as the Head of the Project Management Department. She co-authors 16 scientific publications, one book chapter, and one patent.